John Ioannidis: Unterschied zwischen den Versionen
| [unmarkierte Version] | [gesichtete Version] |
Thomas (Diskussion | Beiträge) |
Thomas (Diskussion | Beiträge) |
||
| Zeile 1: | Zeile 1: | ||
| − | |||
== Veröffentlichungen == | == Veröffentlichungen == | ||
| − | *[https://www.medrxiv.org/content/10.1101/2020.05.13.20101253v3.full.pdf The infection fatality rate of COVID-19 inferred | + | *[https://www.medrxiv.org/content/10.1101/2020.05.13.20101253v3.full.pdf The infection fatality rate of COVID-19 inferred from seroprevalence data] 1.7.2020: <q>Estimates of infection fatality rates inferred from seroprevalence studies tend to be much lower than original speculations made in the early days of the pandemic.</q> |
| + | *[https://www.who.int/bulletin/online_first/BLT.20.265892.pdf Infection fatality rate of COVID-19 inferred from seroprevalence data] 13.5.2020 - 14.10.2020. WHO Version. | ||
*[https://onlinelibrary.wiley.com/doi/10.1111/eci.13484 Assessing Mandatory Stay‐at‐Home and Business Closure Effects on the Spread of COVID‐19] | *[https://onlinelibrary.wiley.com/doi/10.1111/eci.13484 Assessing Mandatory Stay‐at‐Home and Business Closure Effects on the Spread of COVID‐19] | ||
| − | + | ||
[[Category:COVID19 Akteure]] | [[Category:COVID19 Akteure]] | ||
Version vom 26. Januar 2021, 06:37 Uhr
Veröffentlichungen
- The infection fatality rate of COVID-19 inferred from seroprevalence data 1.7.2020:
Estimates of infection fatality rates inferred from seroprevalence studies tend to be much lower than original speculations made in the early days of the pandemic.
- Infection fatality rate of COVID-19 inferred from seroprevalence data 13.5.2020 - 14.10.2020. WHO Version.
- Assessing Mandatory Stay‐at‐Home and Business Closure Effects on the Spread of COVID‐19
